Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors

被引:8
|
作者
Dashora, Umesh [1 ]
Gallagher, Alison [2 ]
Dhatariya, Ketan [3 ]
Winocour, Peter [4 ]
Gregory, Rob [2 ]
机构
[1] Conquest Hosp, Hastings, England
[2] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
[3] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, Norfolk, England
[4] East & North Herts NHS Trust, Stevenage, Herts, England
来源
BRITISH JOURNAL OF DIABETES | 2016年 / 16卷 / 04期
关键词
SGLT-2; inhibitors; diabetic ketoacidosis; ABCD;
D O I
10.15277/bjd.2016.112
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin. The US Food and Drug Administration (FDA) has issued a safety communication following 20 cases of DKA in patients receiving these drugs. 1 This concern has also prompted an American Association of Clinical Endocrinologists and American College of Endocrinology position statement covering the use of SGLT-2 inhibitors in people with type 2 diabetes. 2 The following is the ABCD position statement on this issue.
引用
收藏
页码:206 / +
页数:5
相关论文
共 50 条
  • [41] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
    Heerspink, Hiddo J. L.
    Kosiborod, Mikhail
    Inzucchi, Silvio E.
    Cherney, David Z. I.
    KIDNEY INTERNATIONAL, 2018, 94 (01) : 26 - 39
  • [42] Sodium-glucose cotransporter-2 inhibitors: where and when?
    Cowie, Martin R.
    FUTURE CARDIOLOGY, 2020, 17 (03) : 403 - 406
  • [43] Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
    Profili, Nicia I.
    Castelli, Roberto
    Gidaro, Antonio
    Manetti, Roberto
    Maioli, Margherita
    Delitala, Alessandro P.
    PHARMACEUTICALS, 2024, 17 (11)
  • [44] Association of Sodium-Glucose Cotransporter 2 Inhibitors with Risk of Diabetic Ketoacidosis among Hospitalized PatientsA Multicentre Cohort Study
    Sarma, Shohinee
    Hodzic-Santor, Benazir
    Colacci, Michael
    Verma, Amol A.
    Razak, Fahad
    Raissi, Afsaneh
    Lassen, Mats C. H.
    Fralick, Michael
    DIABETES, 2024, 73
  • [45] RE: Gout and sodium-glucose cotransporter-2 inhibitors
    Lund, Lars Christian
    Hojlund, Mikkel
    Henriksen, Daniel Pilsgaard
    Hallas, Jesper
    Kristensen, Kasper Bruun
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 (01) : 114 - 115
  • [46] Euglycemic Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter-2 Inhibitor Use and Coronary Angiography: A Case Report
    VonTungeln, Christopher D.
    Al Bataineh, Mohammad
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (01)
  • [47] "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report
    Sarno, Myrem Jesame F.
    Hernandez, Dan Philip F.
    Matulac, Melgar O.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [48] Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors
    Takuya Ito
    Gen Sugasawa
    Fumitaka Suzuki
    Masatoshi Sunada
    Kenji Iwamuro
    Takaaki Nakano
    Masahiro Saito
    Satoru Maeba
    Indian Journal of Thoracic and Cardiovascular Surgery, 2022, 38 : 87 - 91
  • [49] Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors
    Ito, Takuya
    Sugasawa, Gen
    Suzuki, Fumitaka
    Sunada, Masatoshi
    Iwamuro, Kenji
    Nakano, Takaaki
    Saito, Masahiro
    Maeba, Satoru
    INDIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2022, 38 (01) : 87 - 91
  • [50] Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis
    Colacci, Michael
    Fralick, John
    Odutayo, Ayodele
    Fralick, Michael
    CANADIAN JOURNAL OF DIABETES, 2022, 46 (01) : 10 - +